Ibezapolstat is currently enrolling in a Phase 2b trial for C. difficile infection in U.S. centers across the country and nearing its goal to reach a targeted.
STATEN ISLAND, N.Y., Aug. 22, 2023 /PRNewswire/ Acurx Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial.
STATEN ISLAND, N.Y., Aug. 14, 2023 /PRNewswire/ Acurx Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial. -Today at 07:02 am- MarketScreener
/PRNewswire/ Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of.
Acurx invites individual and institutional investors, financial advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference.
STATEN ISLAND, N.Y., June. | June 20, 2023